$CPXX Pipeline
CELATOR’S PROPRIETARY TECHNOLOGY PLATFORMS ARE FILLING A GROWING PIPELINE OF INNOVATIVE PRODUCTS TO IMPROVE OUTCOMES FOR PATIENTS WITH CANCER.
The current development pipeline includes novel, clinical-stage combination products and drug discovery programs based on the CombiPlex® platform, as well as a preclinical single-agent candidate that utilizes proprietary nanoparticle delivery technology. CPX-351, Celator’s lead combination product candidate, is currently in a Phase 3 registration study in patients with secondary acute myeloid leukemia (AML).
CPX-351
CPX-351 PROVIDES A PROMISING DEMONSTRATION OF THE ADVANTAGES OF THE COMBIPLEX® PLATFORM AND MAY BECOME THE FIRST TREATMENT IN OVER 40 YEARS TO IMPROVE OVERALL SURVIVAL IN PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML).
CPX-351 (cytarabine:daunorubicin) Liposome for Injection
CPX-351 is a liposomal formulation of a synergistic 5:1 molar ratio of cytarabine and daunorubicin, two agents commonly used to treat blood cancers, particularly AML. The “7+3” combination regimen of cytarabine and daunorubicin is the current standard of care for AML.
Preclinical Research Confirmed the Pharmacokinetic Advantages of CombiPlex®
Research with cancer cell lines has shown that cytarabine:daunorubicin administered in a 5:1 ratio delivers optimal anti-cancer activity, while this combination of chemotherapeutic drugs delivered in other ratios can be antagonistic.
Market Data 
Markets 
